Molecular Oncology
Volume 4, Issue 5 , Pages 451-457, October 2010

Progress in understanding melanoma propagation

  • Mark Shackleton

      Affiliations

    • Melanoma Research Laboratory and Department of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne 3002, Australia
    • Department of Pathology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville 3010, Australia
    • Howard Hughes Medical Institute, Life Sciences Institute, Department of Internal Medicine and Center for Stem Cell Biology, University of Michigan, Ann Arbor, MI 48109-2216, USA
    • Corresponding Author InformationCorresponding author. Melanoma Research Laboratory and Department of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne 3002, Australia. Tel.: +61 3 9656 5235; fax: +61 3 9656 1411.
  • ,
  • Elsa Quintana

      Affiliations

    • Howard Hughes Medical Institute, Life Sciences Institute, Department of Internal Medicine and Center for Stem Cell Biology, University of Michigan, Ann Arbor, MI 48109-2216, USA
    • Present address: Departamento de Farmacología, Facultad de Medicina, Universidad de Valencia, Avd. Blasco Ibáñez, Valencia, Spain.

Received 12 May 2010; received in revised form 15 June 2010; accepted 16 June 2010. published online 02 July 2010.

Abstract 

Melanoma, like most cancers, is a disease that wreaks havoc mostly through its propensity to spread and establish secondary tumors at sites that are anatomically distant from the primary tumor. The consideration of models of cancer progression is therefore important to understand the essence of this disease. Previous work has suggested that melanoma may propagate according to a cancer stem cell (CSC) model in which rare tumorigenic and bulk non-tumorigenic cells are organized into stable hierarchies within tumors. However, recent studies using assays that are more permissive for revealing tumorigenic potential indicate that it will not be possible to cure patients by focusing research and therapy on rare populations of cells within melanoma tumors. Studies of the nature of tumorigenic melanoma cells reveal that these cells may gain a growth, metastasis and/or therapy resistance advantage by acquiring new genetic mutations and by reversible epigenetic mechanisms. In this light, efforts to link the phenotypes, genotypes and epigenotypes of melanoma cells with differences in their in vivo malignant potential provide the greatest hope of advancing the exciting progress finally being made against this disease.

Keywords: Melanoma, Cancer stem cell, Clonal evolution, Interconversion, Plasticity, CD133

Abbreviations: CSC, Cancer Stem Cell, NSG, NOD/SCID IL2Rγ−/−, NK, Natural Killer

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1574-7891(10)00054-2

doi:10.1016/j.molonc.2010.06.006

Molecular Oncology
Volume 4, Issue 5 , Pages 451-457, October 2010